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Background-—Cardiovascular risk factors have differential effects on various manifestations of cardiovascular disease, but to date
direct formal comparisons are scarce, have been conducted primarily in men, and include only traditional risk factors.
Methods and Results-—Using data from the multi-ethnic Women’s Health Initiative Observational Study, we used a case–cohort
design to compare 1731 women with incident cardiovascular disease during follow-up to a cohort of 1914 women. The direction of
effect of all 24 risk factors (including various apolipoproteins, hemoglobin A1c, high-sensitivity C-reactive protein, N-terminal pro-
brain natriuretic peptide, and tissue plasminogen activator antigen) was concordant for coronary heart disease (CHD, deﬁned as
myocardial infarction and CHD death) and ischemic stroke; however, associations were generally stronger with CHD. Signiﬁcant
differences for multiple risk factors, including blood pressure, lipid levels, and measures of inﬂammation, were observed when
comparing the effects on hemorrhagic stroke with those on ischemic outcomes. For instance, multivariable adjusted hazard ratios
per standard deviation increase in non–high-density lipoprotein cholesterol were 1.16 (95% conﬁdence interval, 1.06–1.28) for
CHD, 0.97 (0.88–1.07) for ischemic stroke, and 0.76 (0.63–0.91) for hemorrhagic stroke (P<0.05 for equal association). Model
discrimination was better for models predicting CHD or ischemic stroke than for models predicting hemorrhagic stroke or a
combined end point.
Conclusions-—Cardiovascular risk factors have largely similar effects on incidence of CHD and ischemic stroke in women, although
the magnitude of association varies. Determinants of ischemic and hemorrhagic stroke substantially differ, underscoring their
distinct biology. Cardiovascular disease risk may be more accurately reﬂected when combined cardiovascular disease or
cerebrovascular outcomes are broken down into different ﬁrst manifestations, or when restricted to ischemic outcomes. ( J Am
Heart Assoc. 2018;7:e007514. DOI: 10.1161/JAHA.117.007514.)
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I n many studies, cardiovascular disease (CVD) incidencerepresents the ﬁrst manifestation among a variety of
events combined into a composite end point. This is done under
the assumption that cardiovascular risk factors contribute in a
similar fashion to the development of different manifestations
of CVD. Previous work, however, has shown that CVDmanifests
differentially in men and women. CVD is more likely to manifest
with stroke in women, whereas with coronary heart disease
(CHD) in men.1 Less is known with regard to cardiovascular risk
factors in relation to CVD manifestations. This is important,
since hypertension appears to be preferentially associated with
incidence of stroke, whereas hypercholesterolemia may play a
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more important role in the development of CHD.2–4 Consistent
divergent associations between total cholesterol and high-
density lipoprotein (HDL) cholesterol with risk of ischemic
stroke and intracerebral hemorrhage have been reported,4,5
which likely explains the overall lack of association between
lipid levels and combined stroke outcomes in many popula-
tions. Overall, direct formal comparisons of the effects of
cardiovascular risk factors on the development of various ﬁrst
manifestations of CVD are scarce, were done in men only, and
included only traditional risk factors.6,7 Besides a single report
on only 468 events,3 none of the studies to date have reported
on the differential impact of cardiovascular risk factors on
multiple vascular territories in women.2,4
Differential effects of risk factors may have implications for
causative and prognostic research, as well as for identifying
high-risk individuals and subsequent preventive treatment in
clinical practice. Therefore, we sought to directly examine
differences in effects of traditional and newer cardiovascular
risk factors—representative of a wide spectrum of patho-
physiological pathways—for various ﬁrst common CVD man-
ifestations in a multi-ethnic cohort of women.
Methods
Availability of Data, Analytic Methods, and Study
Materials
The statistical code is available from the corresponding author or
lead author upon reasonable request for purposes of reproducing
the results or replicating the procedure (npaynter@partners.org
or m.leening@erasmusmc.nl, respectively). WHI-OS (The
Women’s Health Initiative Observational Study) case–cohort
data will not be made publicly available for purposes of
reproducing the results. Procedures to requests access to the
WHI-OS data by qualiﬁed researchers can be found online.8
Study Design, Setting, and Population
TheWHI-OS includes 93 676 ethnically diverse postmenopausal
women aged 50 to 79 years at enrollment.9 Women were
recruited at 40 clinical centers throughout the United States
between 1994 and 1998 and followed through 2005. Additional
follow-up was collected through the WHI Extension Study. Of the
WHI-OS participants, 71 872hadnohistory of hardCVD (deﬁned
as myocardial infarction [MI], stroke, revascularization proce-
dures, or peripheral vascular disease), venous thromboem-
bolism, or cancer at baseline. Baseline blood specimens and risk
factor information were available on 60 890 of these women.
A prospective case–cohort design was used (Figure 1).10
Selected cases included all cases of major ﬁrst CVD (deﬁned
as MI, stroke, and cardiovascular death) for blacks/African
Americans (n=200), Hispanics/Latinos (n=53), Asians/Paciﬁc
Islanders (n=55), and women of other or unknown ethnicity
(n=55). For reasons of efﬁciency, the remaining 1637 of 2000
cases were randomly sampled from the 2370 cases among
non-Hispanic white women. A reference subcohort of 2000
women comprised controls selected using the same eligibility
criteria and stratiﬁed to match cases by race/ethnicity and
5-year age categories. After further exclusion for 1 or more
missing laboratory measurements (n=88), white blood cell
count >15 000/lL (n=8),11 lack of follow-up (n=8), or baseline
history of other CVD (n=381; deﬁned as angina, transient
ischemic attack, vascular surgery, heart failure, or resuscitated
cardiac arrest), there were 1731 cases and a subcohort of
1914 women (of whom 130 were also included in the cases
because of the case–cohort design) available for analysis.
Ethical Approval
All participants of the WHI-OS provided informed consent
using materials approved by Institutional Review Boards at
each of the 40 participating centers. This project was
approved by the Institutional Review Board at the Brigham
and Women’s Hospital, Boston, MA.
Clinical Perspective
What Is New?
• Cardiovascular risk factors have differential effects on
various manifestations of cardiovascular disease, but to
date direct formal comparisons have been conducted
primarily in men and include only traditional risk factors.
• Traditional and newer cardiovascular risk factors have
largely similar effects on the incidence of coronary heart
disease and ischemic stroke in women, although the
magnitude of association differs.
• Determinants of ischemic and hemorrhagic stroke substan-
tially differ, underscoring their distinct biology.
• Model discrimination was better for models predicting
coronary heart disease or ischemic stroke risk than for
models predicting hemorrhagic stroke risk or a combined
cardiovascular disease end point.
What Are the Clinical Implications?
• Risk prediction models combining ischemic and hemor-
rhagic stroke into a single composite outcome have a
poorer ability to identify individuals at increased risk of all
stroke types combined because of the differences in risk
factor proﬁles of ischemic and hemorrhagic stroke.
• Global cardiovascular disease risk can be more accurately
estimated when combined cardiovascular or cerebrovascu-
lar outcomes are broken down into different ﬁrst manifes-
tations, or when a composite end point is restricted to
ischemic outcomes only.
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Assessment of CVD Outcomes
Self-reported outcome data through September 2008 were
conﬁrmed centrally through medical record review by trained
physicians.12 MI and coronary death were combined for the
CHD outcome. Medical records, ECGs, and cardiac enzyme
and troponin levels were used for conﬁrmation. Stroke was
deﬁned as sudden-onset persistent neurologic deﬁcit with
Figure 1. Flowchart for selection of participants in the case–cohort design. CVD indicates cardiovascular disease.
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neuro-imaging correlate or lasting >24 hours, and compatible
with obstruction or rupture of the cerebral vascular system in
the absence of other causes. Strokes were classiﬁed as
ischemic or hemorrhagic based on neuro-imaging reports in
all but 91 women. We analyzed those 91 strokes as part of
the ischemic stroke outcome based on the greater prior
probability of these events to be ischemic. Deaths were
classiﬁed on the basis of death certiﬁcates, medical records,
and autopsy reports. In 13 women, MI and stroke were
diagnosed on the same date. These women were considered
as CHD cases in the present analyses.
Assessment of Cardiovascular Risk Factors
Personal and family medical history were collected by
questionnaire at baseline, including self-reported diabetes
mellitus (both treated and untreated),13 family history of a
premature MI (deﬁned as MI before age 55 years in men
and 65 years in women), and smoking. Participants were
asked to bring current medications to clinic visits to assess
medication use. Resting blood pressure, weight, height,
waist circumference, and hip circumference were all mea-
sured at the baseline visit.9 Waist circumference was
measured at the natural waist over nonbinding undergar-
ments at the end of exhalation. Body mass index was
calculated as weight in kilograms divided by height in
meters squared. Alcohol consumption was collected using
the WHI food frequency questionnaire. The food frequency
questionnaire was compared with means of four 24-hour
dietary recalls and a 4-day food record and were found to
have high reliability.14 Alcohol use was categorized as
nondrinking, light drinking (<7 drinks per week), and
moderate to heavy drinking (7 drinks per week or more).
Nondrinking was considered the reference in all analyses.
Physical activity was assessed by self-administered
questionnaire of recreational activity types. The energy
expenditure associated with each activity was calculated
using reported frequency and duration multiplied by inten-
sity in metabolic equivalent hours from standardized
classiﬁcations.15 Energy expenditure from all recreational
physical activity was combined into a weekly total score.16
The physical activity questions were repeated for a subset
of participants and the total expenditure in metabolic
equivalent hours was found to have a weighted j of 0.77.9
Plasma samples collected at study baseline were stored at
70°C and sent to a central laboratory certiﬁed by the
Centers for Disease Control–National Heart Lung and Blood
Institute Lipid Standardization Program. Details regarding the
following measurements are provided in Data S1: total
cholesterol, high-density lipoprotein (HDL) cholesterol,
apolipoprotein A-I (Apo A-I), apolipoprotein B100, lipoprotein
(a), glycated hemoglobin A1c (among diabetics), high-
sensitivity C-reactive protein (hs-CRP), lipoprotein-associated
phospholipase A2 mass concentration, lipoprotein-associated
phospholipase A2 activity, N-terminal pro-brain natriuretic
peptide (NT-proBNP), and human tissue plasminogen activator
antigen. A white blood cell count was obtained by local
laboratories at each study site at the time of the baseline
clinic visit.
Statistical Analysis
We estimated median levels and proportions for cardiovas-
cular risk factors among cases and the subcohort of
controls, both crude and after reweighting to reﬂect the
total WHI-OS cohort. Our method of stratiﬁed sampling from
the known distribution in the full WHI-OS cohort enabled us
to estimate the characteristics of the full sample by
reweighting using the sampling frequency in this case–
cohort design.17,18 Because of skewed distributions, we used
the natural log of metabolic equivalent hours of physical
activity, lipoprotein (a), white blood cell count, hs-CRP, NT-
proBNP, and tissue plasminogen activator antigen levels. For
continuous variables, SDs were derived from the subcohort.
Pearson correlations were computed incorporating the
sampling weights.
We examined the relation between cardiovascular risk
factors and the separate ﬁrst CVD manifestations using
previously described methods for proportional hazards
regression in case–cohort studies with appropriate weighting
of the observations.19 We used weighted Cox regression to
compute hazard ratios,20 and we computed asymptotic
variance estimates.21 Results are presented for models that
were adjusted for age and race/ethnicity. In a separate
model, we additionally adjusted for the following traditional
risk factors at baseline: treated and untreated systolic blood
pressure, total and HDL cholesterol levels, diabetes mellitus,
and smoking status.22 In order to avoid issues with co-
linearity of predictors, we speciﬁed a separate multivariable
model for apolipoprotein A-I and apolipoprotein B100 in which
we did not adjust for total and HDL cholesterol. In addition,
we used forward selection to ﬁt models for each outcome
separately to identify individual factors with the strongest
statistically signiﬁcant effects.
When studying ﬁrst manifestations of CVD, the occurrence
of 1 manifestation precludes consideration of any subsequent
CVD event in the setting of primary prevention of CVD since
follow-up is censored at the occurrence of a ﬁrst event. Such
preclusion of disease-speciﬁc outcomes by other outcomes is
referred to as competing risks.23,24 We used the data
augmentation proposed by Lunn and McNeil to enable direct
comparisons between the effect estimates of risk factors on
speciﬁc ﬁrst CVD manifestations by Cox regression.20,21,25
This allows inference on the difference between
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cause-speciﬁc hazard ratios of individual risk factors for
particular competing ﬁrst CVD manifestations.24
We assessed the predictive ability of the risk markers in
our study for the overall combined CVD outcome, CHD, and
stroke types, separately. The ﬁt of the models was evaluated
using appropriate weighting. We quantiﬁed the discriminatory
ability using a weighted version of the overall survival
c-statistic.26 Conﬁdence intervals were quantiﬁed with 1000
bootstrap repetitions. Age and race/ethnicity were forced into
all the models because of the sampling of the case–cohort
data. All other selected predictors in the ﬁnal multivariate
models remained statistically signiﬁcant at the P<0.05 level.
We used a level of signiﬁcance of P<0.05. All measures of
association are presented with 95% conﬁdence intervals (95%
CI). Data were analyzed using SAS version 9.3 (SAS Institute
Inc, Cary, NC) and the mstate package in R version 3.1.1.27
Results
The baseline characteristics of the women in the subcohort
and the CVD cases are described in Table 1. The average age
was 67.7 (SD 6.7) years, 4.4% of the subcohort was
diagnosed with diabetes mellitus, 25.7% used blood pres-
sure–lowering drugs, 8.1% used statins, and 21.4% used
aspirin. Table S1 includes reweighted characteristics to reﬂect
the sampling from the underlying WHI-OS population.
Among the 1784 women in the subcohort who did not
develop CVD, the median (25th–75th percentile) follow-up time
was 9.9 (8.7–11.8) years. Of the 1731 ﬁrst CVD cases, 703
were CHD (526 clinical nonfatal MIs and 177 CHD deaths), 871
were strokes (714 ischemic and 157 hemorrhagic) and 157
other cardiovascular deaths. Of the 714 ischemic strokes, 623
were conﬁrmed and 91 were probable ischemic but underlying
cause could not be deﬁnitively adjudicated.
Nonlaboratory Risk Factors
All nonlaboratory risk factors were signiﬁcantly associated
with both CHD and ischemic stroke after adjustment for age
and race/ethnicity (Table S2 and Figure S1). Measures of
obesity, diabetes mellitus, and family history of premature MI
were not predictive of hemorrhagic stroke. Further, although
differences were not statistically signiﬁcant, all other nonlab-
oratory risk factors were less predictive for hemorrhagic
stroke as compared with the atherosclerotic outcomes.
In the multivariable models adjusted for traditional
cardiovascular risk factors, physical activity and measures
of obesity were no longer predictive of CHD (Figure 2A and
Table 2). Age and systolic blood pressure were the only
nonlaboratory predictors that signiﬁcantly related to both
types of stroke. In addition, diabetes mellitus and smoking
were associated with ischemic stroke, whereas diastolic
blood pressure was preferentially associated with hemor-
rhagic stroke. The difference in b coefﬁcients between the 2
stroke types and CHD is shown in Figure 2B. Dots to the
left of the vertical line indicate a less harmful association for
the stroke type compared with CHD, while dots to the right
of the line indicate a more harmful association for the
stroke type compared with CHD. Generally, larger differ-
ences were seen when comparing risk factor associations
for CHD with those for hemorrhagic stroke, than for the
comparisons of CHD to ischemic stroke. Systolic blood
pressure had a signiﬁcantly stronger effect on the develop-
ment of ischemic stroke as compared with CHD, whereas
diastolic blood pressure had a much stronger effect on
hemorrhagic stroke as compared with CHD or ischemic
stroke. Effect estimates of diabetes mellitus and family
history of premature MI were signiﬁcantly lower, in fact
inverse, for hemorrhagic stroke as compared with CHD. The
pattern of risk factor associations for other CVD death
resembled that of CHD, with notable greater effects for
measures of obesity and current smoking. Patterns were
similar for white and black women (Table S3).
Laboratory-Based Risk Factors
With the exception of lipoprotein (a), all laboratory-based risk
factors were predictive of CHD after adjustment for demo-
graphic factors (Table S4). Most laboratory markers were
predictive of ischemic stroke. Non-HDL cholesterol, the
apolipoproteins, and NT-proBNP stood out as signiﬁcantly
different from CHD (Figure S2). Directions of effect were
largely similar for CHD and ischemic stroke. Increasing levels
of non-HDL cholesterol and apolipoprotein B100 were associ-
ated with a signiﬁcantly lower risk of developing hemorrhagic
stroke. Markers of inﬂammation and diabetes mellitus control
were not predictive of hemorrhagic stroke. Levels of tissue
plasminogen activator were not associated with either form of
stroke and its risk estimates were signiﬁcantly different from
that for CHD.
In order to determine the effect of a small number of
women with NT-proBNP and hs-CRP levels that could be
considered in pathologically high ranges, these women were
excluded from analysis (Data S1). The effect estimates did not
materially change, and therefore the ﬁndings were not driven
by a small number of CVD cases in women with extremely
high levels of these risk factors.
Adjustment for other CVD risk factors generally lowered
the effect estimates of the laboratory markers across all
outcomes (Figure 3A and Table 3). Higher lipid levels
remained associated with lower risk of hemorrhagic stroke.
Both lipoprotein-associated phospholipase A2 mass and NT-
proBNP remained signiﬁcantly associated with all outcomes
under study. The effect estimates of inﬂammatory markers
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Table 1. Baseline Characteristics of the Case–Cohort Sample of the WHI Observational Study Stratiﬁed by First CVD Manifestation
Subcohort CHD Ischemic Stroke Hemorrhagic Stroke Other CVD Death
n=1914 n=703 n=714 n=157 n=157
Age, y 69 (63–73) 68 (63–73) 69 (64–73) 68 (61–72) 70 (64–74)
Race/ethnicity
Black 183 (9.6) 65 (9.3) 69 (9.7) 18 (11.5) 15 (9.6)
White 1578 (82.5) 584 (83.1) 587 (82.2) 125 (79.6) 129 (82.2)
Hispanic 55 (2.9) 15 (2.1) 19 (2.7) 6 (3.8) 5 (3.2)
Asian 49 (2.6) 14 (2.0) 25 (3.5) 4 (2.6) 6 (3.8)
Other/unknown 49 (2.6) 25 (3.6) 14 (2.0) 4 (2.6) 2 (1.3)
Family history of premature MI 331 (17.3) 173 (24.6) 148 (20.7) 26 (16.6) 34 (21.7)
Smoking
Never 1019 (53.2) 319 (45.4) 371 (52.0) 79 (50.3) 68 (43.3)
Past 809 (42.3) 321 (45.7) 289 (40.5) 67 (42.7) 67 (42.7)
Current 86 (4.5) 63 (9.0) 54 (7.6) 11 (7.0) 22 (14.0)
Alcohol use
Nondrinking 561 (29.3) 246 (35.0) 235 (32.9) 45 (28.7) 58 (36.9)
Light drinking 1095 (57.2) 357 (50.8) 385 (53.9) 93 (59.2) 80 (51.0)
Moderate/heavy drinking 258 (13.5) 100 (14.2) 94 (13.2) 19 (12.1) 19 (12.1)
Physical activity, METs/wk 10 (4–20) 8 (2–17) 8 (3–18) 11 (4–22) 6 (1–17)
Body mass index, kg/m2 25.8 (23.2–29.4) 26.9 (23.8–31.0) 26.3 (23.6–30.1) 26.4 (23.2–29.3) 27.0 (24.1–31.3)
Waist circumference, cm 82 (75–92) 86 (77–96) 85 (77–95) 82 (75–90) 87 (77–97)
Waist–hip ratio 0.80 (0.76–0.85) 0.82 (0.77–0.88) 0.82 (0.77–0.87) 0.80 (0.76–0.85) 0.83 (0.78–0.88)
Systolic blood pressure, mm Hg 128 (117–140) 132 (121–147) 135 (123–149) 131 (120–145) 132 (121–143)
Diastolic blood pressure, mm Hg 74 (68–80) 75 (69–82) 76 (70–82) 78 (70–82) 76 (70–82)
Use of blood pressure–lowering medication 491 (25.7) 264 (37.6) 266 (37.3) 46 (29.3) 57 (36.3)
Total cholesterol, mg/dL 225 (200–257) 229 (200–260) 221 (197–248) 216 (193–240) 231 (200–256)
HDL cholesterol, mg/dL 55 (45–67) 49 (40–60) 48 (39–59) 52 (43–65) 51 (42–62)
Apo A-I, mg/dL 176 (152–206) 167 (145–192) 172 (149–200) 169 (150–200) 167 (150–196)
Apo B100, mg/dL 97 (82–116) 102 (87–123) 98 (82–114) 92 (75–106) 101 (84–121)
Lp(a), mg/dL 12.4 (5.2–30.9) 12.6 (5.1–38.5) 11.2 (5.0–32.6) 12.5 (4.4–31.5) 13.2 (6.3–33.4)
Use of statins 155 (8.1) 55 (7.8) 55 (7.7) 9 (5.7) 9 (5.7)
Use of aspirin 409 (21.4) 180 (25.6) 175 (24.5) 41 (26.1) 30 (19.1)
Diabetes mellitus 84 (4.4) 85 (12.1) 66 (9.2) 6 (3.8) 12 (7.6)
HbA1c (if diabetic), % 7.0 (6.3–8.0) 7.4 (6.7–8.6) 7.7 (6.9–9.6) 6.9 (5.5–8.4) 8.0 (7.1–8.8)
White blood cell count, 103/lL 5.6 (4.8–6.7) 6.1 (5.0–7.2) 6.0 (5.0–7.2) 5.6 (4.5–6.8) 6.3 (5.2–7.5)
hs-CRP, mg/L 2.27 (1.03–4.86) 3.12 (1.42-6.02) 2.98 (1.34–6.19) 1.99 (0.98–4.02) 3.51 (1.76–6.70)
Lp-PLA2 activity, mmol/min per mL 182 (150–214) 195 (164–227) 183 (153–217) 177 (152–206) 196 (166–226)
Lp-PLA2 mass concentration, ng/mL 482 (396–587) 512 (428–628) 524 (427–622) 489 (411–592) 502 (410–605)
NT-proBNP, pg/mL 101 (60–173) 109 (65–191) 130 (70–239) 117 (70–181) 151 (87–311)
tPA antigen, ng/mL 6.27 (3.44–11.37) 6.61 (3.74–13.42) 6.24 (3.33–10.81) 5.03 (3.21–9.19) 7.02 (3.69–15.18)
Values are counts (percentages) or medians (25th–75th percentile). See Table S1 for baseline characteristics reweighted to the full WHI population. Apo indicates apolipoprotein; CHD,
coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Lp(a), lipoprotein (a); Lp-
PLA2, lipoprotein-associated phospholipase A2; METs, metabolic equivalent hours; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; tPA, tissue plasminogen
activator; WHI, Women’s Health Initiative.
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were inverse for hemorrhagic stroke than for all other
outcomes (Figure 3B). We observed similar patterns for white
and black women (Table S5).
Multivariable Models
HDL cholesterol, lipoprotein-associated phospholipase A2
mass, and NT-proBNP were the only markers that were highly
predictive of all outcomes in the multivariable models
(Table 4). Current smoking, systolic blood pressure, and hs-
CRP only contributed to identifying the atherosclerotic
outcomes, whereas diastolic blood pressure was the only
risk factor speciﬁc to predicting hemorrhagic stroke. Selec-
tion of the most predictive markers for each of the outcomes
resulted in higher c-statistics for CHD (0.788; 95% CI, 0.771–
0.793) and ischemic stroke (0.810; 95% CI, 0.795–0.826)
Figure 2. Multivariable adjusted hazard ratios and differences in multivariable adjusted b-estimates
between coronary heart disease and stroke hazards for nonlaboratory risk factors on the incidence of ﬁrst
cardiovascular manifestations. A, Values are multivariable-adjusted cause-speciﬁc hazard ratios of CHD
(closed diamonds), ischemic stroke (closed squares), and hemorrhagic stroke (open circles). Hazard ratios
are expressed per 1 (log-transformed) SD increase for continuous risk factors. See Table 2 for
corresponding cause-speciﬁc hazard ratios. B, Values are differences in multivariable-adjusted b-
estimates25 between hazards of CHD and ischemic stroke (closed squares), and between CHD and
hemorrhagic stroke (open circles). Estimates are expressed per 1 (log-transformed) SD increase for
continuous risk factors. Differences in b-estimates >0 represent greater hazards (or less protective). CHD
hazards are considered the reference. Estimates (95% CIs) were adjusted for age, race/ethnicity, treated
and untreated systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and smoking
status. CHD indicates coronary heart disease; CIs, conﬁdence intervals; MI, myocardial infarction. *P<0.05
for equal association with CHD.25 †P<0.05 for equal association with ischemic stroke.25
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than for the overall combined CVD end point (0.782; 95% CI,
0.771–0.793). The discriminatory ability of the hemorrhagic
stroke-speciﬁc model was somewhat lower with a c-statistic
of 0.754 (95% CI, 0.721–0.788).
The overall combined CVD model had only slightly lower
discriminative ability when applied to predict CHD only
(c-statistic 0.782; 95% CI, 0.766–0.799) and ischemic stroke
only (c-statistic 0.802; 95% CI, 0.786–0.817) as compared with
the respective outcome-speciﬁc models. The performance of the
combined CVD model was markedly worse when applied to
predict hemorrhagic stroke (c-statistic 0.694; 95% CI, 0.656–
0.735) as comparedwith the hemorrhagic stroke-speciﬁcmodel.
Cardiovascular and Noncardiovascular Mortality
During follow-up 50 women in the subcohort died of CVD and
131 of non-CVD causes. In an additional 448 women, their
sampled CVD event resulted in death within 28 days. This
resulted in a total of 498 deaths caused by CVD in the
mortality analyses. When looking at the speciﬁcity of CVD risk
factors to differentiate between CVD and non-CVD mortality,
we noted that almost all risk factors were predictive of CVD
mortality, with hs-CRP and NT-proBNP showing the strongest
associations (Table S6). Hazard ratios were generally lower for
non-CVD mortality, with only current smoking and
apolipoprotein A-I reaching the level of statistical signiﬁcance.
Measures of obesity, blood pressure, hs-CRP, and NT-proBNP
were preferentially associated with CVD death as compared
with non-CVD death.
Discussion
We used long-term follow-up data from a multi-ethnic cohort of
women to study a variety of putative cardiovascular risk
factors. This is the largest study to date on this subject and,
thereby, facilitated direct comparison of risk markers with each
other and across different ﬁrst CVD manifestations within a
single population. Our results indicate that cardiovascular risk
factors generally have largely similar associations with risk of
CHD and ischemic stroke; however, the effect sizes varied. We
noted prominent differences in risk factor proﬁles for hemor-
rhagic stroke, which resulted in a diminished ability to identify
women at increased overall CVD risk.
Context
Previous studies on differential effects of risk factors were
done in men or only included traditional risk factors.4,6,7
The studies in men compared CHD and stroke, but did not
differentiate between ischemic and hemorrhagic stroke.6,7
Table 2. Multivariable Adjusted Hazard Ratios for Nonlaboratory Risk Factors on the Incidence of First Cardiovascular
Manifestations
Risk Marker
CVD CHD Ischemic Stroke Hemorrhagic Stroke Other CVD Death
n=1731 n=703 n=714 n=157 n=157
Age (per SD) 1.92 (1.81–2.05) 1.86 (1.70–2.03) 1.98 (1.82–2.17) 1.63 (1.40–1.92)* 2.32 (1.95–2.76)†,‡
Black race (vs white) 1.20 (0.98–1.48) 1.15 (0.85–1.55) 1.21 (0.91–1.62) 1.38 (0.82–2.32) 1.29 (0.73–2.28)
Light alcohol consumption 0.84 (0.71–1.00) 0.77 (0.62–0.96) 0.92 (0.74–1.15) 1.06 (0.71–1.56) 0.66 (0.45–0.97)
Moderate to heavy alcohol consumption 0.91 (0.70–1.19) 0.89 (0.64–1.24) 1.03 (0.74–1.44) 0.89 (0.49–1.64) 0.60 (0.33–1.10)
Physical activity (per Ln SD) 0.96 (0.88–1.04) 0.95 (0.85–1.06) 0.97 (0.87–1.07) 1.06 (0.88–1.28) 0.83 (0.69–1.01)
Body mass index (per SD) 0.99 (0.91–1.07) 1.03 (0.93–1.14) 0.90 (0.81–1.01)† 0.90 (0.74–1.08) 1.23 (1.05–1.46)†,*,‡
Waist circumference (per SD) 1.00 (0.92–1.09) 1.03 (0.93–1.15) 0.95 (0.86–1.06) 0.89 (0.74–1.08) 1.23 (1.03–1.46)*,‡
Waist–hip ratio (per SD) 1.07 (0.99–1.16) 1.06 (0.96–1.18) 1.09 (0.98–1.21) 0.94 (0.78–1.15) 1.14 (0.98–1.34)
Current smoking 2.87 (2.07–3.98) 3.22 (2.18–4.76) 2.35 (1.57–3.52) 1.83 (0.91–3.67) 5.59 (3.19–9.79)*,‡
Former smoking 1.19 (1.02–1.39) 1.34 (1.10–1.63) 1.06 (0.87–1.28)† 1.11 (0.79–1.57) 1.33 (0.93–1.90)
Systolic blood pressure (per SD) 1.29 (1.18–1.40) 1.23 (1.11–1.36) 1.39 (1.25–1.54)† 1.26 (1.06–1.51) 1.17 (0.98–1.40)
Diastolic blood pressure (per SD) 0.98 (0.89–1.07) 0.94 (0.84–1.06) 0.96 (0.85–1.07) 1.24 (1.01–1.53)†,* 1.02 (0.83–1.25)
Diabetes mellitus 1.71 (1.25–2.35) 2.27 (1.58–3.26) 1.49 (1.02–2.19)† 0.70 (0.29–1.69)† 1.40 (0.71–2.72)
Family history of premature MI 1.33 (1.09–1.61) 1.51 (1.19–1.91) 1.24 (0.97–1.58) 0.92 (0.59–1.44)† 1.36 (0.89–2.06)
Hazard ratios (95% CIs) were adjusted for age, race/ethnicity, treated and untreated systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and current smoking. CHD,
coronary heart disease; CIs, conﬁdence intervals; CVD, cardiovascular disease; HDL, high-density lipoprotein; Ln, natural log-transformed; MI, myocardial infarction.
*P<0.05 for equal association with ischemic stroke.25
†P<0.05 for equal association with CHD.25
‡P<0.05 for equal association with hemorrhagic stroke.25
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Therefore, it is challenging to compare the results of these
studies with our ﬁndings. A consistent ﬁnding across all
studies is the markedly stronger association of age with
stroke and other CVD death as compared with CHD. This is
in line with the observation that CHD as a ﬁrst manifes-
tation of CVD occurs relatively more frequently in younger
individuals, whereas older women who experience a ﬁrst
CVD event are more likely to be diagnosed with stroke or
other CVD death.1
NT-proBNP was the strongest biomarker in our study
related to overall CVD risk and was signiﬁcantly associated
with each CVD manifestation under study. NT-proBNP is a
Figure 3. Multivariable adjusted hazard ratios and differences in b-estimates between coronary heart
disease and stroke hazards for laboratory-based risk factors on the incidence of ﬁrst cardiovascular
manifestations. A, Values are multivariable adjusted cause-speciﬁc hazard ratios of CHD (closed diamonds),
ischemic stroke (closed squares), and hemorrhagic stroke (open circles). Hazard ratios are expressed per 1
(log-transformed) SD increase. See Table 3 for corresponding cause-speciﬁc hazard ratios. B, Values are
differences in multivariable adjusted b-estimates25 between hazards of CHD and ischemic stroke (closed
squares), and between CHD and hemorrhagic stroke (open circles). Estimates are expressed per 1 (log-
transformed) SD increase. Differences in b-estimates >0 represent greater hazards (or less protective).
CHD hazards are considered the reference. Estimates (95% CIs) were adjusted for age, race/ethnicity,
treated and untreated systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and
smoking status. Apo indicates apolipoprotein; CHD, coronary heart disease; HbA1c, glycated hemoglobin
A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Lp(a), lipoprotein (a); Lp-PLA2,
lipoprotein-associated phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; tPA, tissue
plasminogen activator; WBC, white blood cell. *P<0.05 for equal association with CHD.25 †P<0.05 for equal
association with ischemic stroke.25
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marker of cardiac wall stress and as such is introduced into
clinical practice as a diagnostic and prognostic biomarker for
heart failure. However, population studies have not only
identiﬁed NT-proBNP as a strong predictor of heart failure, but
also other CVD events in healthy individuals.28–30 Elucidating
the underlying mechanism for the stronger effect of NT-
proBNP on stroke as compared with CHD requires further
work. Subclinical atrial ﬁbrillation and ventricular dysfunction
have been recently postulated as mechanisms through which
NT-proBNP affects stroke risk.31,32 NT-proBNP and CRP have
previously been identiﬁed as the 2 strongest biomarkers,
among 30 others, for CVD risk prediction in 2 European
populations.33 Notably, we found that both these biomarkers
are also among the few that are very CVD-speciﬁc when we
compared their effects on different causes of death. Such
speciﬁcity is relevant for potential risk stratiﬁcation, espe-
cially in elderly who are at substantial risk of death from non-
CVD causes.
Prediction of each end point separately led to slightly
better discrimination in our analysis when we allowed b
coefﬁcients for the risk factors to vary for CHD and stroke.
This strategy of decomposing overall CVD risk prediction has
previously been shown to improve the accuracy of risk
models.34,35 Another advantage of this approach is that it can
provide clinicians and patients with information on how the
CVD risk is built up.34 Information on whether an individuals’
overall CVD risk is driven by either coronary risk or stroke risk
may matter for individualized preventive treatment. For
instance, in a large meta-analysis, statin use may confer a
greater risk reduction on CHD than on stroke (relative risk
0.76 for CHD versus 0.85 for ischemic stroke, and nonsignif-
icant increased risk with hemorrhagic stroke),36 whereas a
number of blood pressure–lowering agents confer a greater
relative risk reduction on stroke than CHD.37 The preferential
association of lipids with CHD and of blood pressure with
stroke we observe is therefore in line with the data from these
intervention studies.
Hemorrhagic Stroke
In large population studies and trials, multiple cardiovascu-
lar manifestations are often combined into a composite
CVD end point in order to increase statistical power. This is
done under reasonable assumptions that cardiovascular risk
factors (or interventions modifying cardiovascular risk factor
levels) contribute in a similar fashion to the occurrence of
various types of CVD. Our results conﬁrm that risk factor
patterns for CHD and ischemic stroke are largely similar
with congruent directions of effect. However, we noted
clear differences in the risk factor pattern for hemorrhagic
Table 3. Multivariable Adjusted Hazard Ratios for Laboratory-Based Risk Factors on the Incidence of First Cardiovascular
Manifestations
Risk Marker
CVD CHD Ischemic Stroke Hemorrhagic Stroke Other CVD Death
n=1731 n=703 n=714 n=157 n=157
Non-HDL cholesterol (per SD) 1.04 (0.97–1.12) 1.16 (1.06–1.28) 0.97 (0.88–1.07)* 0.76 (0.63–0.91)*,† 1.11 (0.94–1.31)‡
HDL cholesterol (per SD) 0.68 (0.63–0.74) 0.69 (0.62–0.77) 0.63 (0.57–0.71) 0.79 (0.65–0.94)† 0.75 (0.62–0.91)
Apo A-I (per SD)§ 0.82 (0.76–0.89) 0.75 (0.67–0.83) 0.89 (0.81–0.98)* 0.86 (0.72–1.02) 0.85 (0.71–1.01)
Apo B100 (per SD)
§ 1.05 (0.97–1.13) 1.22 (1.11–1.34) 0.95 (0.86–1.05)* 0.70 (0.58–0.84)*,† 1.15 (0.97–1.35)†,‡
Lp(a) (per Ln SD) 1.01 (0.93–1.09) 1.04 (0.94–1.15) 0.97 (0.88–1.07) 0.96 (0.80–1.14) 1.08 (0.91–1.29)
HbA1c if diabetic (per SD) 1.33 (0.98–1.81) 1.16 (0.83–1.62) 1.54 (1.09–2.18)* 0.86 (0.32–2.33) 1.48 (0.87–2.54)
White blood cell count (per Ln SD) 1.16 (1.06–1.27) 1.16 (1.03–1.30) 1.21 (1.08–1.35) 0.85 (0.70–1.04)*,† 1.34 (1.10–1.64)‡
hs-CRP (per Ln SD) 1.20 (1.11–1.30) 1.21 (1.09–1.34) 1.23 (1.11–1.35) 0.86 (0.73–1.02)*,† 1.50 (1.26–1.80)*,†,‡
Lp-PLA2 activity (per SD) 1.07 (0.97–1.17) 1.15 (1.03–1.29) 0.95 (0.85–1.06)* 1.10 (0.89–1.34) 1.24 (1.01–1.52)
†
Lp-PLA2 mass (per SD) 1.25 (1.15–1.36) 1.20 (1.08–1.33) 1.32 (1.18–1.46) 1.40 (1.17–1.67) 1.08 (0.90–1.29)
†,‡
NT-proBNP (per Ln SD) 1.40 (1.29–1.53) 1.26 (1.13–1.40) 1.46 (1.31–1.63)* 1.25 (1.04–1.51) 1.99 (1.67–2.38)*,†,‡
tPA antigen (per Ln SD) 0.98 (0.91–1.06) 1.03 (0.93–1.13) 0.93 (0.85–1.03) 0.87 (0.73–1.04) 1.13 (0.96–1.33)†,‡
Hazard ratios (95% CIs) were adjusted for age, race/ethnicity, treated and untreated systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and smoking status. Apo
indicates apolipoprotein; CHD, coronary heart disease; CIs, conﬁdence intervals; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-
sensitivity C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; tPA,
tissue plasminogen activator.
*P<0.05 for equal association with CHD.25
†P<0.05 for equal association with ischemic stroke.25
‡P<0.05 for equal association with hemorrhagic stroke.25
§Apo A-I and Apo B100 substituted non-HDL cholesterol and HDL cholesterol.
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stroke in both directionality and magnitude of effects.
Non-HDL cholesterol and apolipoprotein B100 were positively
associated with CHD, but inversely associated with hemor-
rhagic stroke. In line with our results, the recent work in
the EPIC-Norfolk population study indicated increased risks
of low-density lipoprotein cholesterol on CHD and to a
lesser extent ischemic stroke, but protective effects on
hemorrhagic stroke.4 These results are also consistent with
a previous analysis of 3 large prospective cohort studies,
including >15 000 women, showing inverse associations of
Table 4. b-Estimates and P Values for Signiﬁcant Cardiovascular Risk Factors on the Incidence of First Cardiovascular
Manifestations in Final Models Based on Forward Selection of Predictors
Risk Marker
CVD CHD Ischemic Stroke Hemorrhagic Stroke
n=1731 n=703 n=714 n=157
Forced predictors
Age (per SD) 0.547, <0.0001 0.574, <0.0001 0.550, <0.0001 0.437, <0.0001
Race/ethnicity (black vs white) 0.404, 0.001 0.265, 0.10 0.334, 0.056 0.482, 0.074
Race/ethnicity (other vs white) 0.236, 0.0474 0.161, 0.34 0.180, 0.28 0.098, 0.74
Nonlaboratory–based risk factors
Light alcohol consumption  0.208, 0.038  
Moderate/heavy alcohol consumption    
Physical activity (per Ln SD)    
Body mass index (per SD)    
Waist circumference (per SD)    
Waist-hip ratio (per SD) 0.112, 0.0074  0.140, 0.006 
Current smoking 0.874, <0.0001 1.015, <0.0001 0.707, 0.0008 
Former smoking  0.223, 0.030  
Systolic blood pressure (per SD) 0.239, <0.0001 0.227, <0.0001 0.301, <0.0001 
Diastolic blood pressure (per SD)    0.284, 0.0009
Diabetes mellitus 0.573, 0.0008 0.884, <0.0001  
Family history of premature MI 0.266, 0.0082 0.398, 0.001  
Laboratory-based risk factors
Non-HDL cholesterol (per SD)    
HDL cholesterol (per SD) 0.375, <0.0001 0.366, <0.0001 0.454, <0.0001 0.264, 0.005
Apo A-I (per SD)    
Apo B100 (per SD)   0.241, <0.0001 0.553, <0.0001
Lp(a) (per Ln SD)    
HbA1c if diabetic (per SD)   0.414, 0.0015 
White blood cell count (per Ln SD)    
hs-CRP (per Ln SD) 0.169, <0.0001 0.224, <0.0001 0.210, <0.0001 
Lp-PLA2 activity (per SD)    
Lp-PLA2 mass (per SD) 0.214, <0.0001 0.230, <0.0001 0.330, <0.0001 0.369, <0.0001
NT-proBNP (per Ln SD) 0.341, <0.0001 0.197, 0.0004 0.380, <0.0001 0.235, 0.012
tPA antigen (per Ln SD)   0.104, 0.048 
C-statistic (95% CI) 0.782 (0.771–0.793) 0.788 (0.771–0.805) 0.810 (0.795–0.826) 0.754 (0.721–0.788)
Age and race/ethnicity were forced into the models because these were the sampling parameters for the selection in the case–cohort design. In order to avoid co-linearity, we only allowed
for waist–hip ratio, waist circumference, or body mass index; either non-HDL cholesterol or Apo B100; either HDL cholesterol or Apo A-I; and either Lp-PLA2 activity or Lp-PLA2 mass
concentration. Apo indicates apolipoprotein; CI, conﬁdence interval; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity
C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain
natriuretic peptide; tPA, tissue plasminogen activator.
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total cholesterol with the risk of hemorrhagic stroke.5 Also
mirroring our results, this study found no relation between
diabetes mellitus and hemorrhagic stroke. These differences
in risk factor proﬁles highlight the distinct biology of
hemorrhagic stroke from other atherosclerotic CVD mani-
festations. As a consequence, risk models combining
ischemic and hemorrhagic stroke into a composite outcome
have a poorer ability to identify individuals at increased risk
of all stroke types combined.
Despite the different risk proﬁle associated with hemor-
rhagic stroke, the global cardiovascular risk calculators
advocated by the American College of Cardiology/American
Heart Association and European Society of Cardiology to
identify candidates for statin therapy do not distinguish
between stroke types.35,38 The addition of ischemic stroke to
the previous CHD calculator was called for by several US
research councils.39 This is relevant since statins and aspirin
decrease the risk of ischemic stroke.36,40 Yet, statins do not
reduce the risk of hemorrhagic stroke (or might even increase
hemorrhagic stroke risk),41 and aspirin is associated with
increased risk of intracranial bleeding.40 For that reason, the
most recent guidelines on aspirin use in primary prevention of
CVD recommend to estimate bleeding risk and CVD risk
separately in order to assess the anticipated net clinical
beneﬁt of long-term aspirin use.42
We acknowledge that often it is difﬁcult to make a clear
distinction between ischemic and hemorrhagic stroke, given
that the clinical syndrome is very similar. Limited clinical
information or lack of neuro-imaging poses a challenge for
stroke typing in clinical research. In the present analysis,
10.4% of the strokes could not be further categorized. A
common way to overcome this is to analyze unspeciﬁed
strokes as if they were of ischemic origin based on prior
probability,5,43 rather than making no distinction at all and
combine all strokes into a composite outcome.
Limitations
A number of limitations need to be considered. Our results
were generated from a single cohort with baseline measures
collected in a particular era of available treatments. This
cohort included only women; thus, the generalizability of our
ﬁndings is limited because of the sex differences in ﬁrst
manifestations of CVD.1 Similarly, previous work has shown
that CVD manifests differently in whites and blacks.44 We
did not observe major differences between white and black
women in patterns for most risk factors; however, the
number of cases available in nonwhites was limited. Second,
previous work from the WHI trials has focused on the
differential effects of hormone replacement therapy on
stroke types in women.45,46 Because of the observational
nature of our study, we did not focus on differential effects
of medication use, including hormone replacement therapy
and statins, on the various CVD outcomes. The interpretation
of effect estimates for medication use in observational
data is complicated because it reﬂects a combination of
pharmacological effects, confounding by indication, con-
founding by severity, and a selection bias related to a
positive attitude towards prevention in general, which cannot
be disentangled.47 Third, the CHD and stroke outcomes in
our study included nonfatal and fatal events, whereas the
other CVD outcome only included fatal events. This could
have affected our comparison between the different ﬁrst
manifestations because relative risk estimates between fatal
and nonfatal events may differ. Similarly, risk factor
estimates may differ when strokes are divided into speciﬁc
subtypes, such as based on infarct type or bleeding location.
Fourth, we present a substantial number of statistical
comparisons for equal association. Many of these compar-
isons are correlated or test the same hypothesis using
different biomarkers. For instance, we included multiple
correlated parameters for obesity, dyslipidemia, and inﬂam-
mation. If we take a most conservative approach by
assuming all comparisons are completely independent and
hypothesis free, 9 comparisons in the fully adjusted models
in Figure 3 would remain statistically signiﬁcant at a
Bonferroni threshold of P<0.00139. Next, data on repeated
measurements of risk factors were unavailable for the
majority of risk factors. Therefore, we used baseline
measurements of biomarkers throughout the analyses. Last,
for a number of outcomes, such as hemorrhagic stroke and
non-CVD mortality, we had a limited number of events
available for analysis. This resulted in a limited statistical
power to detect small differences in effect estimates.
Conclusions
In summary, in middle-aged and older women free of CVD,
both traditional and newer cardiovascular risk factors have
largely similar effects on the incidence of atherosclerotic CVD
manifestations, although the magnitude of associations may
vary. However, determinants of ischemic and hemorrhagic
stroke substantially differ, underscoring their distinct biology.
Our ﬁndings suggest that CVD risk may be more accurately
reﬂected when combined CVD or cerebrovascular outcomes
are broken down into different ﬁrst manifestations, or when
the composite end point is restricted to ischemic outcomes
only.
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Data S1. 
 
Assessment of blood biomarkers 
Plasma samples collected at study baseline were stored at -70 °C and sent to a central laboratory certified by 
the Centers for Disease Control-National Heart Lung and Blood Institute Lipid Standardization Program.  
Total cholesterol was measured enzymatically.1 At cholesterol concentrations of 132.8 mg/dL and 
280.4 mg/dL, the day-to-day reproducibility in our laboratory, reflected by the coefficient of variation, is 1.7% 
and 1.6%, respectively. The average coefficient of variation (using the overall pooled within-person variance 
and the overall mean) based on 201 blind duplicate WHI samples was 8.5%.2 
High-density lipoprotein (HDL) cholesterol was measured using direct enzymatic colorimetric assay 
with polyethylene glycol (PEG)-modified cholesterol oxidase and esterase.3, 4 The coefficients of variation at 
HDL cholesterol concentrations of 27.0 mg/dL and 54.9 mg/dL are 3.3% and 1.7%, respectively. The average 
coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 201 
blind duplicate WHI samples was 9.7%.2 Non-HDL cholesterol levels were calculated by subtracting HDL 
cholesterol levels from total cholesterol levels. 
Apolipoprotein A-I (Apo A-I) was measured using an immunoturbidimetric technique on the Hitachi 
917 analyzer (Roche Diagnostics, Indianapolis, IN, U.S.), using reagents and calibrators from Wako Chemicals 
(Richmond, VA, U.S.). The coefficients of variation at Apo A-I concentrations of 63.7 mg/dL, 126.7 mg/dL, and 
177.4 mg/dL are 1.2%, 2.8%, and 3.3%, respectively. The average coefficient of variation (using the overall 
pooled within-person variance and the overall mean) based on 201 blind duplicate WHI samples was 9.4%.2 
Apolipoprotein B100 (Apo B100) was measured using an immunoturbidimetric technique on the Hitachi 
917 analyzer (Roche Diagnostics, Indianapolis, IN, U.S.), using reagents and calibrators from Wako Chemicals 
(Richmond, VA, U.S.). The coefficients of variation at Apo B100 concentrations of 42.6 mg/dL, 88.3 mg/dL, and 
132.8 mg/dL are 5.1%, 3.9%, and 4.0%, respectively. The average coefficient of variation (using the overall 
pooled within-person variance and the overall mean) based on 201 blind duplicate WHI samples was 9.2%.2 
Lipoprotein (a) (Lp(a)) was measured using a turbidimetric assay on the Hitachi 917 analyzer (Roche 
Diagnostics, Indianapolis, IN, U.S.), using reagents and calibrators from Denka Seiken (Niigata, Japan). This 
method is the only commercial assay that is not affected by the Kringle Type 2 repeats.5 The coefficients of 
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variation at Lp(a) concentrations of 17.6 mg/dL and 58.1 mg/dL are 3.6% and 1.5%, respectively. The average 
coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 200 
blind duplicate WHI samples was 13.9% for Lp(a) and 5.4% for natural log-transformed (Ln) Lp(a).2 
Hemoglobin A1c (HbA1c) was measured in lysed red blood cells of diabetic women only using 
turbidimetric immunoinhibition on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN, U.S.). The 
reported result is a calculation of the percentage HbA1c in the total hemoglobin. The coefficients of variation at 
HbA1c values of 5.5% and 9.1% are 1.9% and 3.0%, respectively. The average coefficient of variation (using the 
overall pooled within-person variance and the overall mean) based on 15 blind duplicate WHI samples was 
2.4%.2 
High-sensitivity C-reactive protein (hs-CRP) was measured using an immunoturbidimetric assay on the 
Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN, U.S.), using reagents and calibrators from DiaSorin 
(Stillwater, MN, U.S.). This assay has a sensitivity of 0.03 mg/L. The coefficients of variation of the assay at 
concentrations of 0.91 mg/L, 3.07 mg/L, and 13.38 mg/L are 2.8%, 1.6%, and 1.1%, respectively. The average 
coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 201 
blind duplicate WHI samples was 6.2% for hs-CRP and 3.6% for Ln hs-CRP.2 In order to account for extreme 
values in hs-CRP that would indicate active underlying inflammatory disease, we repeated the main analysis 
after excluding 160 women with hs-CRP >20 mg/L. 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity was measured in a 96-well microplate with 
a colorimetric substrate that is converted on hydrolysis by the phospholipase enzyme. Lp-PLA2 mass 
concentration was measured with the automated PLAC test using a latex bead-based immunoturbidimetric 
assay, which uses 2 monoclonal antibodies specific to Lp-PLA2 in a sandwich assay format. Reagents for both 
assays were provided by diaDexus (South San Francisco, CA, U.S.) free of charge. Coefficients of variation based 
on laboratory standards are 4.0% for Lp-PLA2 activity and 5.9% for Lp-PLA2 mass.6 The average coefficients of 
variation (using the overall pooled within-person variance and the overall mean) based on 201 blind duplicate 
WHI samples were 4.7% for Lp-PLA2 activity and 12.6% for Lp-PLA2 mass concentration.2 
N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured using a quantitative sandwich 
electrochemiluminescent enzyme immunoassay technique on the 2010 Elecsys immunoanalyzer (Roche 
Diagnostics, Indianapolis, IN, U.S.).7 The coefficients of variation at NT-proBNP concentrations of 175 pg/mL, 
434 pg/mL, and 6781 pg/mL are 3.2%, 2.4%, and 2.2%, respectively. The average coefficient of variation (using 
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the overall pooled within-person variance and the overall mean) based on 201 blind duplicate WHI samples 
was 12.1% for NT-proBNP and 1.8% for Ln NT-proBNP.2 In order to account for extreme values in NT-proBNP 
that would indicate underlying heart failure, we repeated the main analysis after excluding 64 women with 
age-specific diagnostic levels of NT-proBNP for acute heart failure (>900 pg/mL for age ≤75 years and >1800 
pg/mL for age >75 years).7, 8  
Human tissue plasminogen activator (tPA) antigen was measured using an ELISA assay (American 
Diagnostica, Greenwich, CT, U.S.), an enzymatically amplified 'two-step' sandwich-type immunoassay. This 
assay has a sensitivity of 2.0 ng/mL. For the present analysis, 410 women (11.7%) with non-detectable levels of 
tPA antigen were considered to have a level of 1.80 ng/mL. The coefficients of variation of the assay at tPA 
antigen concentrations of 6.0 ng/mL and 15.0 ng/mL is 5.5% and 4.9%, respectively. The average coefficient of 
variation (using the overall pooled within-person variance and the overall mean) based on 173 blind duplicate 
WHI samples was 45.5% for tPA and 15.0% for Ln tPA.2  
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Table S1. Reweighted baseline characteristics of the case-cohort sample of the Women’s Health Initiative Observational 
Study stratified by first CVD manifestation. 
    Subcohort CHD Ischemic stroke 
Hemorrhagic 
stroke Other CVD death 
       
  n = 53 252 n = 946 n = 957 n = 209 n = 211 
              
Age, years 62 (56-68) 68 (63-72) 68 (64-72) 68 (61-72) 69 (64-74) 
Race/ethnicity: black 3674 (6.9) 65 (6.9) 69 (7.2) 18 (8.6) 15 (7.1) 
 white 45 327 (85.1) 827 (87.4) 830 (86.7) 177 (84.7) 183 (86.7) 
  Hispanic 1821 (3.4) 15 (1.6) 19 (2.0) 6 (2.9) 5 (2.4) 
 Asian 1581 (3.0) 14 (1.5) 25 (2.6) 4 (1.9) 6 (2.9) 
  other/unknown 850 (1.6) 25 (2.6) 14 (1.5) 4 (1.9) 2 (1.0) 
Family history of premature MI 9801 (18.4) 237 (25.1) 205 (21.4) 34 (16.5) 47 (22.2) 
Smoking: never 27 398 (51.5) 429 (45.3) 496 (51.8) 104 (49.8) 91 (43.4) 
 past 23 189 (43.5) 436 (46.1) 393 (41.1) 90 (43.2) 91 (43.2) 
  current 2665 (5.0) 81 (8.5) 69 (7.2) 15 (7.0) 28 (13.5) 
Alcohol use: non-drinking 14 019 (26.3) 323 (34.1) 305 (31.9) 59 (28.4) 75 (35.5) 
  light drinking 31 553 (59.3) 484 (51.2) 523 (54.6) 122 (58.7) 109 (51.7) 
 
moderate/heavy 
drinking 7680 (14.4) 138 (14.6) 130 (13.6) 27 (12.9) 27 (12.8) 
Physical activity, METs/week 9 (3-20) 8 (2-17) 8 (2-17) 10 (3-21) 6 (1-16) 
Body mass index, kg/m2 25.9 (23.1-29.9) 26.9 (23.7-30.9) 26.3 (23.6-30.1) 26.2 (23.0-29.2) 26.9 (24.0-31.1) 
Waist circumference, cm 82 (74-92) 86 (77-96) 84 (76-95) 81 (75-90) 87 (77-97) 
Waist-hip ratio 0.79 (0.75-0.85) 0.82 (0.77-0.87) 0.82 (0.77-0.87) 0.80 (0.75-0.85) 0.82 (0.77-0.88) 
Systolic blood pressure, mmHg 123 (114-135) 132 (120-146) 134 (123-148) 130 (120-144) 132(120-142) 
Diastolic blood pressure, mmHg 74 (69-80) 74 (68-81) 75 (69-82) 77 (70-82) 75 (69-81) 
Use of blood pressure lowering 
medication 11 254 (21.1) 351 (37.1) 352 (36.8) 61 (29.3) 76 (36.0) 
Total cholesterol, mg/dL 225 (200-258) 228 (201-260) 221 (197-248) 216 (192-239) 232 (199-255) 
HDL cholesterol, mg/dL 55 (46-67) 49 (40-60) 48 (39-59) 52 (42-65) 51 (42-62) 
Apo A-I, mg/dL 177 (151-208) 167 (145-192) 172 (149-200) 169 (150-201) 168 (150-197) 
Apo B100, mg/dL 97 (81-116) 102 (87-123) 98 (82-114) 91 (75-107) 101 (84-121) 
Lp(a), mg/dL 11.4 (5.0-28.6) 12.0 (5.0-37.8) 10.7 (4.6-31.8) 12.3 (4.4-30.9) 12.8 (5.8-33.3) 
Use of statins 3562 (6.7) 73 (7.7) 74 (7.8) 12 (5.7) 13 (6.0) 
Use of aspirin 9772 (17.6) 247 (26.2) 242 (25.3) 56 (27.0) 42 (19.1) 
Diabetes mellitus 1718 (3.2) 107 (11.3) 84 (8.8) 7 (3.5) 16 (7.5) 
HbA1c (if diabetic), % 6.9 (6.2-8.0) 7.4 (6.7-8.4) 7.7 (6.8-9.2) 6.4 (5.5-8.2) 7.8 (7.1-8.8) 
White blood cell count, 103/uL 5.5 (4.7-6.6) 6.1 (5.0-7.2) 5.9 (5.0-7.2) 5.5 (4.5-6.8) 6.2 (5.1-7.5) 
hs-CRP, mg/L 2.32 (1.01-5.07) 3.09 (1.42-5.98) 2.99 (1.34-6.18) 1.99 (0.96-4.03) 3.49 (1.74-6.22) 
Lp-PLA2 activity, mmol/min/mL 178 (145-211) 195 (163-226) 184 (154-217) 177 (152-207) 196 (165-226) 
Lp-PLA2 mass concentration, 
ng/mL 474 (383-570) 513 (430-627) 524 (428-623) 489 (416-596) 497 (409-605) 
NT-proBNP, pg/mL 82 (51-135) 110 (65-190) 132 (72-240) 118 (70-183) 151 (87-310) 
tPA antigen, ng/mL 5.90 (3.13-11.39) 6.58 (3.74-13.23) 6.18 (3.30-10.73) 5.02 (3.21-9.21) 6.88 (3.67-14.80) 
              
 
Values are counts (percentages) or medians (25th-75th percentile). Total numbers may not add up due to rounding. Apo, 
apolipoprotein; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-
density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated 
phospholipase A2; METs, metabolic equivalent hours; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain 
natriuretic peptide; tPA, tissue plasminogen activator.  
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Table S2. Hazard ratios for non-laboratory risk factors on the incidence of first cardiovascular manifestations. 
Risk marker CVD CHD Ischemic stroke Hemorrhagic stroke Other CVD death 
 n = 1731 n = 703 n = 714 n = 157 n = 157 
            
Age (per SD) 2.03 (1.93-2.14) 1.96 (1.82-2.12) 2.13 (1.97-2.30) 1.70 (1.46-1.98) † 2.35 (1.99-2.76) * ‡ 
Black race (vs. white) 1.50 (1.26-1.79) 1.43 (1.10-1.87) 1.51 (1.17-1.96) 1.68 (1.02-2.78) 1.58 (0.92-2.72) 
Light alcohol consumption 0.77 (0.66-0.90) 0.69 (0.57-0.85) 0.81 (0.67-1.00) 1.03 (0.70-1.51) 0.69 (0.48-0.99) 
Moderate or heavy alcohol consumption 0.80 (0.64-1.01) 0.79 (0.59-1.06) 0.82 (0.61-1.10) 0.90 (0.51-1.60) 0.68 (0.39-1.18) 
Physical activity (per Ln SD) 0.88 (0.81-0.95) 0.86 (0.78-0.95) 0.89 (0.81-0.98) 1.04 (0.87-1.25) 0.77 (0.64-0.92) ‡ 
Body mass index (per SD) 1.19 (1.11-1.27) 1.26 (1.15-1.38) 1.12 (1.03-1.22) * 0.96 (0.81-1.14) * 1.35 (1.17-1.56) † ‡ 
Waist circumference (per SD) 1.25 (1.16-1.34) 1.32 (1.21-1.45) 1.20 (1.10-1.31) 0.97 (0.82-1.15) * † 1.38 (1.19-1.60) ‡ 
Waist-hip ratio (per SD) 1.20 (1.11-1.30) 1.22 (1.11-1.34) 1.21 (1.11-1.32) 1.00 (0.84-1.18) * † 1.22 (1.07-1.39) 
Current smoking 2.57 (1.90-3.48) 2.84 (1.96-4.09) 2.10 (1.44-3.06) 1.82 (0.92-3.59) 4.95 (2.86-8.56) † ‡ 
Former smoking 1.14 (0.99-1.32) 1.30 (1.08-1.56) 1.00 (0.83-1.20) * 1.07 (0.76-1.50) 1.29 (0.91-1.84) 
Systolic blood pressure (per SD) 1.40 (1.30-1.51) 1.37 (1.25-1.50) 1.50 (1.36-1.64) 1.28 (1.08-1.51) 1.27 (1.08-1.50) 
Diastolic blood pressure (per SD) 1.20 (1.12-1.29) 1.15 (1.05-1.26) 1.23 (1.13-1.35) 1.32 (1.12-1.56) 1.17 (0.99-1.38) 
Diabetes mellitus 2.61 (1.95-3.50) 3.41 (2.43-4.79) 2.42 (1.70-3.45) * 0.96 (0.41-2.25) * † 1.94 (1.02-3.70) 
Family history of premature MI 1.40 (1.18-1.67) 1.60 (1.29-1.99) 1.31 (1.05-1.64) 0.96 (0.62-1.50) * 1.41 (0.94-2.12) 
            
 
Hazard ratios (95% CIs) were adjusted for age and race/ethnicity. CHD, coronary heart disease; CVD, cardiovascular disease; Ln, natural log-transformed; MI, myocardial 
infarction; SD, standard deviation. 
* P<0.05 for equal association with CHD.9 
† P<0.05 for equal association with ischemic stroke.9 
‡ P<0.05 for equal association with hemorrhagic stroke.9  
D
ow
nloaded from
 http://ahajournals.org by on November 7, 2018
  
Table S3. Multivariable adjusted hazard ratios for non-laboratory risk factors on the incidence of first cardiovascular manifestations in white and black women. 
Risk marker White women     Black women     
 CVD CHD Ischemic stroke CVD CHD Ischemic stroke 
 n = 1425 n = 584 n = 587 n = 167 n = 65 n = 69 
              
Age (per SD) 1.94 (1.82-2.08) 1.85 (1.68-2.04) 1.97 (1.79-2.17) 1.95 (1.61-2.36) 2.09 (1.58-2.76) 2.04 (1.55-2.70) 
Light alcohol consumption 0.78 (0.64-0.94) 0.69 (0.54-0.89) 0.88 (0.69-1.12) 0.77 (0.44-1.33) 0.93 (0.45-1.93) 0.73 (0.35-1.52) 
Moderate or heavy alcohol consumption 0.80 (0.61-1.05) 0.76 (0.54-1.07) 0.90 (0.63-1.27) 2.19 (0.48-10.07) 3.91 (0.65-23.55) 3.32 (0.53-20.66) 
Physical activity (per Ln SD) 0.92 (0.83-1.01) 0.93 (0.82-1.05) 0.91 (0.81-1.02) 1.05 (0.81-1.36) 1.03 (0.73-1.45) 1.14 (0.81-1.59) 
Body mass index (per SD) 1.01 (0.92-1.11) 1.04 (0.93-1.17) 0.94 (0.84-1.06) 0.85 (0.67-1.09) 0.90 (0.65-1.25) 0.79 (0.56-1.09) 
Waist circumference (per SD) 1.01 (0.92-1.11) 1.01 (0.90-1.13) 0.98 (0.87-1.10) 0.92 (0.71-1.20) 1.04 (0.73-1.48) 0.84 (0.60-1.19) 
Waist-hip ratio (per SD) 1.05 (0.97-1.15) 1.02 (0.92-1.14) 1.09 (0.98-1.21) 1.11 (0.85-1.46) 1.20 (0.85-1.70) 0.95 (0.67-1.34) 
Current smoking 2.64 (1.81-3.83) 2.71 (1.72-4.27) 2.18 (1.35-3.50) 3.03 (1.36-6.76) 3.66 (1.35-9.94) 3.02 (1.11-8.22) 
Former smoking 1.23 (1.04-1.45) 1.35 (1.09-1.67) 1.10 (0.89-1.37) 0.86 (0.51-1.45) 1.00 (0.49-2.02) 0.70 (0.35-1.41) 
Systolic blood pressure (per SD) 1.27 (1.16-1.39) 1.21 (1.08-1.36) 1.37 (1.22-1.52) 1.20 (0.90-1.60) 1.02 (0.70-1.49) 1.37 (0.96-1.97) 
Diastolic blood pressure (per SD) 1.02 (0.92-1.12) 1.01 (0.89-1.15) 1.01 (0.89-1.14) 0.81 (0.60-1.09) 0.61 (0.41-0.92) 0.77 (0.52-1.13) 
Diabetes mellitus 1.46 (1.01-2.12) 1.83 (1.19-2.81) 1.32 (0.84-2.07) 2.75 (1.33-5.69) 4.94 (2.06-11.83) 3.02 (1.22-7.49) 
Family history of premature MI 1.30 (1.06-1.59) 1.47 (1.15-1.88) 1.25 (0.97-1.61) 0.90 (0.42-1.97) 0.94 (0.35-2.51) 0.61 (0.20-1.87) 
              
 
These analyses were restricted to CHD and ischemic stroke in white and black women because of the small number of hemorrhagic strokes and other CVD deaths in non-
whites and small number of events in general in other ethnic groups (Table 1 main manuscript). Hazard ratios (95% CIs) were adjusted for age, treated and untreated 
systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and smoking status. P>0.05 for all comparisons of equal association between CHD and ischemic 
stroke.9 CHD, coronary heart disease; CVD, cardiovascular disease; Ln, natural log-transformed; MI, myocardial infarction; SD, standard deviation.  
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Table S4. Hazard ratios for laboratory-based risk factors on the incidence of first cardiovascular manifestations. 
Risk marker CVD CHD Ischemic stroke Hemorrhagic stroke Other CVD death 
 n = 1731 n = 703 n = 714 n = 157 n = 157 
            
Non-HDL cholesterol (per SD) 1.07 (1.00-1.14) 1.19 (1.09-1.29) 1.01 (0.93-1.11) * 0.78 (0.65-0.93) * † 1.13 (0.96-1.32) ‡ 
HDL cholesterol (per SD) 0.65 (0.60-0.70) 0.64 (0.58-0.71) 0.60 (0.54-0.67) 0.80 (0.67-0.96) * † 0.73 (0.61-0.88) 
Apo A-I (per SD) 0.82 (0.76-0.88) 0.75 (0.68-0.83) 0.88 (0.80-0.97) * 0.84 (0.70-1.00) 0.87 (0.73-1.04) 
Apo B100 (per SD) 1.04 (0.98-1.12) 1.19 (1.09-1.30) 0.97 (0.88-1.06) * 0.70 (0.58-0.84) * † 1.13 (0.97-1.32) ‡ 
Lp(a) (per Ln SD) 0.98 (0.92-1.05) 1.03 (0.94-1.13) 0.94 (0.86-1.03) 0.90 (0.76-1.07) 1.07 (0.90-1.27) 
HbA1c if diabetic (per SD) 1.73 (1.32-2.26) 1.77 (1.33-2.36) 1.81 (1.37-2.39) 0.91 (0.44-1.90) 1.66 (1.13-2.45) 
White blood cell count (per Ln SD) 1.35 (1.24-1.46) 1.39 (1.25-1.54) 1.38 (1.24-1.53) 0.92 (0.76-1.10) * † 1.58 (1.31-1.91) ‡ 
hs-CRP (per Ln SD) 1.29 (1.20-1.39) 1.33 (1.21-1.46) 1.31 (1.20-1.43) 0.89 (0.76-1.05) * † 1.55 (1.31-1.84) ‡ 
Lp-PLA2 activity (per SD) 1.22 (1.13-1.30) 1.34 (1.22-1.47) 1.12 (1.02-1.22) * 1.01 (0.86-1.20) 1.35 (1.15-1.59) † ‡ 
Lp-PLA2 mass (per SD) 1.24 (1.16-1.33) 1.25 (1.14-1.36) 1.27 (1.17-1.39) 1.19 (1.01-1.39) 1.14 (0.97-1.33) 
NT-proBNP (per Ln SD) 1.42 (1.31-1.54) 1.25 (1.13-1.38) 1.49 (1.35-1.65) * 1.30 (1.09-1.56) 2.01 (1.69-2.39) * † ‡ 
tPA antigen (per Ln SD) 1.04 (0.98-1.12) 1.11 (1.02-1.21) 0.99 (0.91-1.08) * 0.87 (0.73-1.04) * 1.19 (1.01-1.39) † ‡ 
            
 
Hazard ratios (95% CIs) were adjusted for age and race/ethnicity. Apo, apolipoprotein; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated 
hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated 
phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator. 
* P<0.05 for equal association with CHD.9 
† P<0.05 for equal association with ischemic stroke.9 
‡ P<0.05 for equal association with hemorrhagic stroke.9 
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Table S5. Multivariable adjusted hazard ratios for laboratory-based risk factors on the incidence of first cardiovascular manifestations in white and black women. 
Risk marker White women     Black women     
 CVD CHD Ischemic stroke CVD CHD Ischemic stroke 
 n = 1425 n = 584 n = 587 n = 167 n = 65 n = 69 
              
Non-HDL cholesterol (per SD) 1.02 (0.95-1.11) 1.16 (1.05-1.28) 0.94 (0.85-1.05) * 1.27 (0.99-1.63) 1.30 (0.93-1.79) 1.40 (1.01-1.92) 
HDL cholesterol (per SD) 0.68 (0.63-0.75) 0.69 (0.61-0.77) 0.64 (0.57-0.72) 0.72 (0.53-0.98) 0.81 (0.54-1.20) 0.66 (0.43-1.01) 
Apo A-I (per SD) † 0.83 (0.77-0.90) 0.75 (0.68-0.84) 0.89 (0.80-0.98) * 0.79 (0.58-1.07) 0.67 (0.43-1.05) 0.92 (0.63-1.33) 
Apo B100 (per SD) † 1.03 (0.95-1.11) 1.20 (1.08-1.32) 0.92 (0.83-1.02) * 1.35 (1.04-1.73) 1.48 (1.04-2.10) 1.42 (1.02-1.97) 
Lp(a) (per Ln SD) 1.03 (0.95-1.12) 1.05 (0.94-1.16) 1.00 (0.90-1.11) 0.93 (0.67-1.28) 1.35 (0.84-2.17) 0.78 (0.51-1.17) * 
HbA1c if diabetic (per SD) 1.63 (1.05-2.52) 1.28 (0.78-2.09) 1.82 (1.09-3.04) 1.53 (0.87-2.68) 1.36 (0.70-2.63) 2.04 (1.05-3.96) 
White blood cell count (per Ln SD) 1.21 (1.10-1.34) 1.19 (1.05-1.36) 1.30 (1.14-1.47) 0.92 (0.71-1.18) 0.93 (0.67-1.29) 0.90 (0.64-1.27) 
hs-CRP (per Ln SD) 1.20 (1.10-1.31) 1.20 (1.07-1.34) 1.25 (1.12-1.39) 1.10 (0.85-1.42) 1.17 (0.83-1.65) 1.11 (0.79-1.54) 
Lp-PLA2 activity (per SD) 1.03 (0.93-1.14) 1.10 (0.97-1.24) 0.92 (0.81-1.05) * 1.22 (0.88-1.69) 1.42 (0.94-2.16) 0.98 (0.66-1.48) 
Lp-PLA2 mass (per SD) 1.26 (1.14-1.38) 1.19 (1.07-1.34) 1.34 (1.19-1.50) 1.10 (0.83-1.45) 1.05 (0.74-1.49) 1.06 (0.76-1.49) 
NT-proBNP (per Ln SD) 1.38 (1.26-1.52) 1.23 (1.09-1.38) 1.47 (1.30-1.65) * 1.55 (1.19-2.01) 1.21 (0.86-1.71) 1.59 (1.14-2.22) 
tPA antigen (per Ln SD) 0.96 (0.89-1.05) 1.01 (0.91-1.12) 0.91 (0.82-1.01) 0.88 (0.68-1.13) 0.91 (0.66-1.25) 0.78 (0.55-1.09) 
              
 
These analyses were restricted to CHD and ischemic stroke in white and black women because of the small number of hemorrhagic strokes and other CVD deaths in non-
whites and small number of events in general in other ethnic groups (Table 1 main manuscript). Hazard ratios (95% CIs) were adjusted for age, treated and untreated 
systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and smoking status. Apo, apolipoprotein; CHD, coronary heart disease; CVD, cardiovascular 
disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein (a); Lp-
PLA2, lipoprotein-associated phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator. 
* P<0.05 for equal association with CHD.9 
† Apo A-I and Apo B100 substituted non-HDL cholesterol and HDL cholesterol.
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Table S6. Hazard ratios for cardiovascular risk factors on the incidence of cardiovascular and non-
cardiovascular death. 
Risk marker CVD death Non-CVD death 
 n = 498 n = 131 
      
Non-laboratory risk factors:   
  Age (per SD) 2.62 (2.38-2.89) 2.80 (2.32-3.39) 
  Black race (vs. white) 1.88 (1.40-2.53) 1.00 (0.49-2.07) 
  Light alcohol consumption 0.74 (0.59-0.93) 0.93 (0.61-1.42) 
  Moderate/heavy alcohol consumption 0.77 (0.55-1.08) 1.20 (0.68-2.11) 
  Physical activity (per Ln SD) 0.82 (0.73-0.92) 0.91 (0.74-1.10) 
  Body mass index (per SD) 1.31 (1.19-1.45) 0.97 (0.80-1.19) * 
  Waist circumference (per SD) 1.37 (1.24-1.51) 1.01 (0.84-1.22) * 
  Waist-hip ratio (per SD) 1.24 (1.12-1.36) 1.03 (0.86-1.24) 
  Current smoking 3.78 (2.53-5.65) 2.76 (1.34-5.71) 
  Former smoking 1.40 (1.13-1.74) 1.37 (0.94-1.99) 
  Systolic blood pressure (per SD) 1.32 (1.20-1.47) 1.07 (0.89-1.28) * 
  Diastolic blood pressure (per SD) 1.18 (1.06-1.30) 0.93 (0.77-1.11) * 
  Diabetes mellitus 2.30 (1.55-3.43) 1.34 (0.60-3.01) 
  Family history of premature MI 1.18 (0.90-1.54) 1.50 (0.97-2.31) 
Laboratory-based risk factors:     
  Non-HDL cholesterol (per SD) 1.06 (0.95-1.17) 1.00 (0.84-1.20) 
  HDL cholesterol (per SD) 0.71 (0.64-0.80) 0.84 (0.70-1.02) 
  Apo A-I (per SD) 0.81 (0.72-0.90) 0.82 (0.67-1.00) 
  Apo B100 (per SD) 1.05 (0.95-1.16) 1.01 (0.85-1.21) 
  Lp(a) (per Ln SD) 0.95 (0.86-1.06) 0.94 (0.78-1.13) 
  HbA1c if diabetic (per SD) 1.77 (1.32-2.37) 1.00 (0.45-2.22) 
  White blood cell count (per Ln SD) 1.38 (1.22-1.55) 1.04 (0.85-1.28) * 
  hs-CRP (per Ln SD) 1.37 (1.23-1.53) 1.10 (0.92-1.32) * 
  Lp-PLA2 activity (per SD) 1.20 (1.09-1.33) 1.17 (0.98-1.40) 
  Lp-PLA2 mass (per SD) 1.11 (1.00-1.22) 1.06 (0.89-1.26) 
  NT-proBNP (per Ln SD) 1.76 (1.57-1.97) 1.07 (0.88-1.31) * 
  tPA antigen (per Ln SD) 1.10 (1.00-1.22) 1.09 (0.91-1.30) 
      
 
We restricted our population for analysis to the subcohort (n=50 deaths due to CVD causes and n=131 deaths 
due to non-CVD causes) and the subset of the sampled CVD cases who died from CVD within 28 days of the 
index event (n=448). Hazard ratios (95% CIs) were adjusted for age and race/ethnicity. Median (25th-75th 
percentile) follow-up time was 10.0 (8.9-11.9) years among the 1707 women in the subcohort who were 
censored alive. Apo, apolipoprotein; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-
density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein 
(a); Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction; NT-proBNP, N-terminal pro-
brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator. 
* P<0.05 for equal association with CVD death.9 
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Figure S1. Differences in β-estimates between coronary heart disease and stroke hazards for non-laboratory 
risk factors on the incidence of first cardiovascular manifestations. 
 
Values are differences in age and race/ethnicity adjusted β-estimates 9 between hazards of CHD and ischemic 
stroke (closed squares) and hemorrhagic stroke (open circles). Estimates are expressed per 1 (log-transformed) 
standard deviation increase for continuous risk factors. Differences in β-estimates greater than 0 represent 
greater hazards (or less protective). CHD hazards are considered the reference. See Table S2 for corresponding 
cause-specific hazard ratios. CHD, coronary heart disease; MI, myocardial infarction.  
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Figure S2. Differences in β-estimates between coronary heart disease and stroke hazards for laboratory-
based risk factors on the incidence of first cardiovascular manifestations. 
 
Values are differences in age and race/ethnicity adjusted β-estimates 9 between hazards of CHD and ischemic 
stroke (closed squares) and hemorrhagic stroke (open circles). Estimates are expressed per 1 (log-transformed) 
standard deviation increase. Differences in β-estimates greater than 0 represent greater hazards (or less 
protective). CHD hazards are considered the reference. See Table S4 for corresponding cause-specific hazard 
ratios. Apo, apolipoprotein; CHD, coronary heart disease; HbA1c, glycated hemoglobin A1c; HDL, high-density 
lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated 
phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; tPA, tissue plasminogen activator; 
WBC, white blood cell.
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